The medication is commonly used in therapeutic domains that involve symptoms related to physical discomfort and systemic imbalance. The medication is used in areas where short-term symptom management is appropriate, particularly for symptoms associated with inflammation and pain. It is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive, including mild to moderate pain (such as headaches and dental discomfort), fever (elevated body temperature), and symptoms related to inflammatory or irritative states (such as swelling and stiffness).

The medication is also commonly used when supportive symptom management is appropriate for cyclical discomfort, specifically the cramping pain of primary dysmenorrhea.

“It is applied in scenarios where additional management of discomfort is required, contributing to easing the overall symptom load.”

This medicine is commonly used across conditions presenting with periods of heightened symptoms, often used during phases when symptoms become more noticeable, providing supportive relief that may assist with improved comfort.

Quick Fact: Relief for Pain, Fever, and Inflammation

Regulatory References

1. Ibuprofen - StatPearls - NCBI Bookshelf - NIH

Ibuprofeno Cinfa (Ibuprofen) eligibility is determined by regulatory authorities based on specific patient populations, age, and pre-existing medical conditions. The official regulatory label defines who is permitted to use the medicine and who must not use it.

Populations Who Must Not Use (Contraindicated)

Use is strictly prohibited for individuals with a known hypersensitivity to Ibuprofen or other NSAIDs, or a history of allergy symptoms like asthma after taking aspirin. It is also contraindicated in patients with severe organ failure (including severe heart failure, severe hepatic, or severe renal failure) and those with active or recurrent gastrointestinal bleeding or peptic ulcers. The medicine must not be used during the third trimester of pregnancy or immediately following CABG surgery.

Age and Conditional Eligibility

The medicine is generally permitted for adults and adolescents (12 years and older), and for children starting from 6 months of age in appropriate formulations. Older adults (60 years and over) require careful monitoring due to a heightened risk of adverse reactions. Patients with uncontrolled high blood pressure, certain cardiovascular diseases, or a history of inflammatory bowel disease must use the medicine only under restrictive conditions as defined by the official label. Use is not recommended for women who are actively trying to conceive.

Interactions with other medicines and products

Ibuprofen, the active ingredient in Ibuprofeno Cinfa, has documented interaction patterns that are classified by regulatory authorities. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is strictly advised to be avoided due to a cumulative and severe risk of gastrointestinal (GI) bleeding and ulceration. A specific mandatory timing rule applies when combining Ibuprofen with low-dose, immediate-release Aspirin used for antiplatelet effect: Ibuprofen must be taken at least 8 hours before or 30 minutes after the Aspirin dose to prevent interference with its therapeutic action.

The medicine affects the plasma concentrations of several co-administered drugs. Ibuprofen is known to increase the plasma levels of Lithium by decreasing its renal clearance and increase the plasma concentrations of Methotrexate by inhibiting its tubular secretion. Concurrent use with Anticoagulants (e.g., Warfarin) and Selective Serotonin Reuptake Inhibitors (SSRIs) significantly increases the risk of major hemorrhage. Additionally, Ibuprofen reduces the blood pressure-lowering effect of Antihypertensives and the diuretic effect of Loop and Thiazide diuretics.

Official labeling advises against the consumption of alcohol while using Ibuprofen due to a documented increased risk of GI bleeding. Regulatory documents also note that the risk of interaction-related nephrotoxicity, particularly in combination with diuretics or antihypertensives, is heightened in the elderly and patients with pre-existing impaired renal, cardiac, or hepatic function.

The function of Ibuprofeno Cinfa relies on the specific mechanism of its active ingredient, Ibuprofen, to modulate key biological pathways responsible for heightened nociceptive signaling and thermoregulatory set-point elevation. Ibuprofen primarily acts as a reversible, non-selective inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, the drug prevents them from producing prostanoids (such as PGE2) from arachidonic acid—the mediators responsible for mediating the sensitization of nociceptors and peripheral vasodilation. This molecular interference modifies the upstream signals in the eicosanoid pathway, resulting in the modulation of nociceptive, thermal, and vascular signaling cascades. The core mechanistic action promotes the resetting of an elevated hypothalamic thermoregulatory set-point, while the restriction of PGE2 at peripheral sites leads to a decrease in nociceptor sensitization and modulation of prostaglandin-mediated changes in vascular permeability and tone.

How Ibuprofeno Cinfa is Used: Official Administration Guidelines

This section outlines the standardized usage instructions for Ibuprofen, the active ingredient in Ibuprofeno Cinfa. This information details the administration procedure but does not cover therapeutic indications or safety information.

Administration and Dosage Parameters

Frequency and Contextual Instructions

Dosing Schedule:

• Doses are typically taken every 4 to 6 hours as needed for acute, short-term symptoms. For chronic conditions, the daily dose is typically divided into three or four intakes per day.
• Short-term use for pain relief should not exceed 10 days without medical advice.

Administration Context:

• Tablets are recommended to be taken with food or milk and a full glass of water to minimize potential gastric irritation.
• Oral Suspensions must be shaken well before measurement, and the dose must be measured using the device provided by the manufacturer to ensure accuracy.

Population-Specific Rules:

• Older Adults and patients with mild to moderate renal or hepatic impairment should initiate therapy with the lowest effective dose.

Research Evidence / Overview of Studies for Ibuprofeno Cinfa

Research concerning Ibuprofen (the active ingredient in Ibuprofeno Cinfa) is well-established, with a foundation built on numerous short-term Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses across its established areas of study. This information describes group patterns observed in the studies but does not provide individual medical advice or clinical predictions.

Evidence for Acute Symptom Relief: Pain and Fever

This section summarizes the core evidence base, primarily focusing on short-term RCTs and associated analyses that was studied for managing mild to moderate acute pain and fever.

Research on Acute Pain Management

Research examined outcomes related to physical discomfort in various acute pain models, including headache, discomfort following minor surgery like dental procedures, and acute musculoskeletal states. These trials, which primarily involved adults and pediatric populations, used standardized scales to measure pain intensity and monitored the time it took for participants to report a change in pain intensity scores.

Studies report how symptoms evolved in the observed populations, comparing outcomes in pain scores between the medicine and inactive treatments (placebo). Furthermore, some research describes patterns where, beyond certain dose amounts, increasing the dose was observed in some studies to correlate with limited further changes in the measured analgesic outcome.

Research on Fever Reduction (Antipyresis)

The evidence base for antipyresis (fever response) primarily comes from RCTs and comparative studies that was studied for this purpose in both adults and children (typically 6 months to 12 years of age) who presented with elevated body temperature. Studies examined outcomes related to systemic imbalance, specifically measuring the change in core body temperature over time. Trials reported measurable changes in core body temperature when comparing the medicine against inactive treatment.

Long-Term Research and Evidence Gaps

While the core uses of the medicine are supported by high-quality RCTs, the research highlights what is known—and what is still uncertain:

• Long-term effects are not fully established for many of the acute uses (pain, fever) because the initial efficacy trials had limited follow-up durations and were designed to study short-term symptom relief.
• Data are still emerging regarding outcomes for daily functioning or activity level over periods longer than 6 months when comparing the medicine to other treatment options for symptomatic inflammatory states.
• Research is ongoing to fully characterize the long-term patterns of use, particularly concerning doses in the high range ( ge 2,400 mg/day).

Key Studies & References

1. World Health Organization Model List of Essential Medicines (Ibuprofen entry)
2. Ibuprofen: StatPearls - NCBI Bookshelf
3. Efficacy and safety of paracetamol versus ibuprofen for treating fever in children: a systematic review and meta-analysis
4. Osteoarthritis: care and management (NICE Guideline NG226)

Common questions about Ibuprofeno Cinfa (FAQ)

Q: How quickly can I expect Ibuprofeno Cinfa to start working?

Studies and official pharmacokinetic information indicate that the active ingredient, Ibuprofen, is rapidly absorbed after oral administration. For standard immediate-release formulations, the medicine typically reaches its highest concentration in the bloodstream within one to two hours. This time frame describes the drug's availability in the body, which typically precedes symptom relief.

Q: How long does the effect of Ibuprofeno Cinfa typically last?

Official information indicates the medicine has a relatively short half-life, which is the time it takes for half of the substance to be eliminated from the body, typically lasting around 1 to 3 hours. This short duration of action is consistent with the drug's elimination profile, which informs official dosing guidelines.

Q: Why is it said that Ibuprofeno Cinfa should be taken with food?

Regulatory documents note that the medicine is often administered with food or milk, particularly the tablet forms. This administration context is advised to help minimize the potential for gastric irritation or upset stomach. This potential side effect is associated with the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: What is the difference between Ibuprofeno Cinfa and paracetamol (acetaminophen)?

According to official pharmacological classifications, Ibuprofeno Cinfa's active ingredient, Ibuprofen, is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Paracetamol (acetaminophen) belongs to a distinctly different class. Paracetamol does not share the same anti-inflammatory properties that are characteristic of NSAIDs.

Q: What happens if I miss a dose of Ibuprofeno Cinfa?

General dosing instructions advise against taking the medicine more frequently than is recommended on the label. If a dose is missed, it is generally advised to take the next dose at the regularly scheduled time. Official instructions advise against taking two doses closely together to compensate for a missed dose.

Q: Is there a maximum amount of Ibuprofeno Cinfa generally recommended over a day?

Regulatory information indicates that for short-term, non-prescription use, the generally recommended maximum daily dose is 1200 mg. For certain medical conditions, higher prescription limits, such as up to 3200 mg in divided doses, are defined in official labeling.

Q: Is it common to feel tired after taking Ibuprofeno Cinfa?

Official patient safety information lists Central Nervous System (CNS) effects like dizziness and headache as uncommon side effects. While general fatigue or drowsiness is not universally listed as common, it may be noted in relation to other CNS effects in some product labeling.

Q: Can Ibuprofeno Cinfa affect my sleep?

Official safety documents classify insomnia, which is difficulty sleeping, as an uncommon adverse reaction associated with the medicine's use. This means it may affect up to 1 in 100 people who use the medicine.

Q: Is Ibuprofeno Cinfa known to interact with herbal supplements?

Official drug interaction guidance often advises caution when combining Ibuprofen with certain herbal supplements. Specifically, supplements known to have blood-thinning properties, such as ginger, garlic, or Ginkgo biloba, may increase the risk of bleeding when taken concurrently.

Q: Are there different warnings for children taking Ibuprofeno Cinfa compared to adults?

Yes, the regulatory labels for pediatric formulations contain warnings specific to children. These warnings often address risks related to potential stomach bleeding and dehydration. Pediatric dosing is always determined based on the child's body weight or age, as defined by official guidelines.

Q: What does 'Cinfa' mean in the drug name?

'Cinfa' refers to the pharmaceutical company that develops, manufactures, and markets this specific product specialty. This name is used to distinguish the product from other brands that contain the same active ingredient, Ibuprofen.

Q: Do official patient leaflets discuss how Ibuprofeno Cinfa is removed from the body?

Yes, official regulatory documents, such as the Summary of Product Characteristics, contain a section on pharmacokinetic properties. This information explains that the medicine is primarily metabolized by the liver into inactive components which are then mostly eliminated from the body through the urine.

Q: Why are there different versions of Ibuprofeno Cinfa (e.g., immediate-release, slow-release)?

Regulatory documents describe various formulations, such as Immediate-Release (IR) and Extended-Release (ER) versions. These versions are designed to provide symptom relief over different durations. The IR form is typically for acute pain, while the ER form is designed for longer, sustained action.

Q: Does Ibuprofeno Cinfa affect blood sugar levels?

While Ibuprofen is not primarily known to affect blood sugar, evidence indicates that high doses of NSAIDs may be associated with a potential for lowering blood sugar levels. Official guidance indicates that this is a factor monitored in certain patient populations.

Q: Does Ibuprofeno Cinfa cause weight gain?

Official patient safety information lists edema, or fluid retention and swelling, as a known adverse reaction. While edema can potentially result in a change in weight, general weight gain is not widely cited as a common side effect of the medicine.

Q: Is Ibuprofeno Cinfa a prescription-only drug?

The medicine is available in common, lower strengths (typically 200 mg) for non-prescription (OTC) use. However, it is also available in higher strengths (e.g., 400 mg or more) that are available for specific medical conditions and are subject to prescription limits.

Q: Is it normal for Ibuprofeno Cinfa to have a specific taste?

Oral liquid suspensions and some chewable tablet forms often contain various flavoring agents as inactive ingredients. These ingredients are included to improve the taste and make the medicine more palatable, which can result in a specific taste.

Q: Are there differences in how liquid and tablet forms of Ibuprofeno Cinfa work?

The active ingredient works through the same mechanism regardless of the form. However, official information suggests that liquid formulations (suspensions or granules) may be absorbed slightly faster than traditional solid tablets. This difference in absorption can potentially result in a quicker onset of effect.

Q: Do regulatory agencies classify Ibuprofeno Cinfa as a high-risk drug?

Regulatory documents do not use the term 'high-risk.' Instead, they define the specific safety profile by including multiple serious warnings and contraindications. These warnings relate to conditions like heart disease, gastrointestinal bleeding, and late-stage pregnancy, and they define the product's safety profile.

Q: Is there evidence that Ibuprofeno Cinfa helps with muscle recovery?

Clinical trial registries show that studies have been conducted to examine the medicine's effect compared to placebo for conditions such as Delayed Onset Muscle Soreness (DOMS). However, official drug labeling does not list muscle recovery as an approved therapeutic indication.

Q: Are there different forms of Ibuprofeno Cinfa available, like creams or gels?

Yes, regulatory documents confirm that Ibuprofen formulations go beyond oral tablets and suspensions. In some regions, Ibuprofen is available as topical gels or creams which are intended for direct application to the skin for local pain relief.

Storage and Disposal Requirements

The storage and disposal instructions for Ibuprofeno Cinfa are defined by regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Disposal Instructions

To protect the environment, the official regulatory instructions strictly forbid discarding the medicinal product into household trash or wastewater. Any unused or expired Ibuprofeno Cinfa must be handled as pharmaceutical waste and disposed of in accordance with local requirements, typically by returning it to a designated pharmacy collection point.